{"id":11887,"date":"2021-03-11T15:49:30","date_gmt":"2021-03-11T10:19:30","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11887"},"modified":"2021-07-24T12:58:18","modified_gmt":"2021-07-24T07:28:18","slug":"pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics","title":{"rendered":"Valo Health receives $110M Series B Cognito&#8217;s therapy slows Alzheimer&#8217;s disease Ventyx Biosciences raises $114M  Takeda expands immuno-oncology portfolio"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f9bedfc0752\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f9bedfc0752\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics\/#Valo_Health_receives_USD_110_Million_Series_B_from_Koch\" >Valo Health receives USD 110 Million Series B from Koch<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics\/#Cognitos_light-and-sound_therapy_slows_Alzheimers_disease_in_the_clinical_study\" >Cognito&#8217;s light-and-sound therapy slows Alzheimer&#8217;s disease in the clinical study<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics\/#Ventyx_bags_USD_114_Million_to_test_drugs_against_hot_immunology_targets\" >Ventyx bags USD 114 Million to test drugs against hot immunology targets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics\/#Takeda_to_expand_immuno-oncology_portfolio_with_Maverick_Therapeutics_Acquisition\" >Takeda to expand immuno-oncology portfolio with Maverick Therapeutics Acquisition<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-valo-health-receives-usd-110-million-series-b-from-koch\"><span class=\"ez-toc-section\" id=\"Valo_Health_receives_USD_110_Million_Series_B_from_Koch\"><\/span><strong>Valo Health receives USD 110 Million Series B from Koch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Valo Health launched in September with USD 100 million and a couple of acquisitions under its belt to transform drug development and cut years off R&amp;D timelines. Now, it is filling with USD 110 million from Koch Disruptive Technologies that will bolster the development of its technology and the discovery and development of its drug programs.<\/p>\n\n\n\n<p>In January, the company raised USD 190 million in the first close of its series B round from The Public Sector Pension Investment Board (PSP Investments), Flagship Pioneering, Invus Public Equities, HBM Healthcare Investments, Atinum Investment, and Mirae Asset Capital. At the time, Valo also revealed the first four preclinical programs it is working on <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-pipeline-insight\">cancer treatments<\/a><\/strong> targeting PARP1, NAMPT, USP28, and HDAC3.\u00a0<\/p>\n\n\n\n<p>Valo CEO David Berry said that its PARP1 program is one example of this best-in-class approach. <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/parp-inhibitors-competitive-landscape-pipeline-and-market-analysis\">PARP inhibitors<\/a><\/strong>, such as AstraZeneca and Merck&#8217;s Lynparza and Zejula from GlaxoSmithKline&#8217;s Tesaro, have seen success in breast and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/advanced-recurrent-ovarian-cancer-market\">ovarian cancers<\/a><\/strong>, but they are peripherally restricted, so they go around the body but do not get in the brain, as said by Berry. That inhibits them from being effectively used to treat cancers that spread to the brain and cancers that begin in the brain.\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cognito-s-light-and-sound-therapy-slows-alzheimer-s-disease-in-the-clinical-study\"><span class=\"ez-toc-section\" id=\"Cognitos_light-and-sound_therapy_slows_Alzheimers_disease_in_the_clinical_study\"><\/span><strong>Cognito&#8217;s light-and-sound therapy slows Alzheimer&#8217;s disease in the clinical study<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Cognito Therapeutics has delivered clinical data from its digital <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight\">treatment for Alzheimer\u2019s disease<\/a><\/strong> patients that relies on light and sound to stimulate specific electrical frequencies in the brain\u2019s neurons, showing it enhanced memory and cognition as well as physical symptoms.<\/p>\n\n\n\n<p>The company\u2019s GammaSense therapy was granted a breakthrough designation by the FDA earlier this year for its goals of reactivating the brain\u2019s immune system and potentially changing the course of the <strong><a href=\"https:\/\/www.delveinsight.com\/blog\/the-growing-burden-of-neurodegenerative-disorders\/\">neurodegenerative disease<\/a><\/strong>.<\/p>\n\n\n\n<p>In the phase 2 trial, 76 participants aged 50 and older with mild or moderate Alzheimer\u2019s signed up to undergo the therapy for one hour each day or receive a placebo treatment.&nbsp;<\/p>\n\n\n\n<p>Described as a strobe light but much faster and coupled with particular audible tones, Cognito\u2019s therapy calibrates with the user\u2019s EEG readings to sync up with and improve the brain\u2019s gamma waves are associated with overall cognitive function.<\/p>\n\n\n\n<p>After six months, researchers found that patients\u2019 declining function scores decreased by about 84% among different metrics compared to placebo. Moreover, MRI imaging uncovered a 61% reduction in whole-brain atrophy and losses of volume in areas associated with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer\u2019s<\/a><\/strong>.<\/p>\n\n\n\n<p>The company also showed that active treatment led to more extended benefits in performing everyday activities and safe therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ventyx-bags-usd-114-million-to-test-drugs-against-hot-immunology-targets\"><span class=\"ez-toc-section\" id=\"Ventyx_bags_USD_114_Million_to_test_drugs_against_hot_immunology_targets\"><\/span><strong>Ventyx bags USD 114 Million to test drugs against hot immunology targets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Ventyx Biosciences, a California-based clinical-stage biotechnology company advancing a broad pipeline of potent and selective small-molecule drug candidates for inflammatory diseases and autoimmune disorders treatment, raised USD 114 Million in funding.<\/p>\n\n\n\n<p>venBio Partners led the round alongside new investors, comprising Third Point, RTW Investments, LP, Janus Henderson Investors, Wellington Management, OrbiMed, Surveyor Capital (a Citadel company), Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners USA, Cormorant Asset Management, and participation from founding investor New Science Ventures. In connection with the financing, Richard Gaster and Aaron Royston of venBio Partners and Jigar Choksey of Third Point will be uniting with the Ventyx Board of Directors.<\/p>\n\n\n\n<p>The company plans to utilise the funds for the clinical development of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/immunologic-deficiency-syndrome-market\">immunology <\/a><\/strong>programs and progress preclinical programs against novel drug targets with its prolific drug discovery engine.<\/p>\n\n\n\n<p>Led by Raju Mohan, Chief Executive Officer, Ventyx operates an internally discovered and wholly-owned portfolio of potent and selective small molecule drug candidates, which target multiple indications in the immunology space, comprising gastrointestinal and dermatological diseases.\u00a0<\/p>\n\n\n\n<p>Moreover, Ventyx is leveraging its drug discovery platform to progress preclinical programs against other biologically relevant targets involved in treating inflammatory diseases and autoimmune disorders.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-takeda-to-expand-immuno-oncology-portfolio-with-maverick-therapeutics-acquisition\"><span class=\"ez-toc-section\" id=\"Takeda_to_expand_immuno-oncology_portfolio_with_Maverick_Therapeutics_Acquisition\"><\/span><strong>Takeda to expand immuno-oncology portfolio with Maverick Therapeutics Acquisition<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Takeda tapped Maverick Therapeutics and its T-cell engager platform in early 2017 to develop new treatments for previously undruggable <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-market\">cancer <\/a><\/strong>targets. The USD 125 million pact also had a 5-year buyout option, which Takeda is now exercising for up to USD 525 million in an upfront fee and development and regulatory milestones.\u00a0<\/p>\n\n\n\n<p>Takeda will takeover Maverick\u2019s COBRA platform and the pipeline the company has built around it, comprising lead candidate MVC-101, now known as TAK-186, in a phase 1\/2 study in solid tumors that express EGFR. The Japanese pharma will also attain MVC-280, now TAK-280, which is poised to enter the clinic in patients with B7H3-expressing solid tumors. Takeda hopes to commence the trial in the second half of its 2021 financial year, which runs from April 2021 to March 2022.&nbsp;<\/p>\n\n\n\n<p>The duo anticipates wrapping the agreement in the April to June time frame, as per the companies\u2019 statement. Maverick employees will be a part of Takeda\u2019s R&amp;D unit upon closing.&nbsp;<\/p>\n\n\n\n<p>The COBRA platform is designed to work only in the tumour microenvironment, so treatments can focus on various kinds of solid tumors while leaving healthy tissues. This sets Maverick\u2019s approach apart from standard <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\">T-cell engager treatments<\/a><\/strong> that are given systemically.\u00a0\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Valo Health receives USD 110 Million Series B from Koch Valo Health launched in September with USD 100 million and a couple of acquisitions under its belt to transform drug development and cut years off R&amp;D timelines. Now, it is filling with USD 110 million from Koch Disruptive Technologies that will bolster the development of [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":11889,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[72,349,420,639,554,18777,18778],"industry":[17225],"therapeutic_areas":[17229,17245],"class_list":["post-11887","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-disease","tag-latest-pharma-news","tag-news","tag-pharma-news","tag-takeda","tag-valo-health","tag-ventyx-biosciences","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Valo bags $110M; Alzheimer&#039;s disase research; Ventyx raises $114M<\/title>\n<meta name=\"description\" content=\"Cognito&#039;s therapy slows Alzheimer&#039;s disease; Ventyx Biosciences raises $114M; Takeda expands immuno-oncology portfolio...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valo bags $110M; Alzheimer&#039;s disase research; Ventyx raises $114M\" \/>\n<meta property=\"og:description\" content=\"Cognito&#039;s therapy slows Alzheimer&#039;s disease; Ventyx Biosciences raises $114M; Takeda expands immuno-oncology portfolio...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-11T10:19:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/11154355\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Valo bags $110M; Alzheimer's disase research; Ventyx raises $114M","description":"Cognito's therapy slows Alzheimer's disease; Ventyx Biosciences raises $114M; Takeda expands immuno-oncology portfolio...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics","og_locale":"en_US","og_type":"article","og_title":"Valo bags $110M; Alzheimer's disase research; Ventyx raises $114M","og_description":"Cognito's therapy slows Alzheimer's disease; Ventyx Biosciences raises $114M; Takeda expands immuno-oncology portfolio...","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-03-11T10:19:30+00:00","article_modified_time":"2021-07-24T07:28:18+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/11154355\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics","name":"Valo bags $110M; Alzheimer's disase research; Ventyx raises $114M","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/11154355\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics.jpg","datePublished":"2021-03-11T10:19:30+00:00","dateModified":"2021-07-24T07:28:18+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Cognito's therapy slows Alzheimer's disease; Ventyx Biosciences raises $114M; Takeda expands immuno-oncology portfolio...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/11154355\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/11154355\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics.jpg","width":772,"height":482,"caption":"pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/11154355\/pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Takeda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Valo Health<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ventyx Biosciences<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Takeda<\/span>","<span class=\"advgb-post-tax-term\">Valo Health<\/span>","<span class=\"advgb-post-tax-term\">Ventyx Biosciences<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 11, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 11, 2021 3:49 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11887"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11887\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11889"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11887"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11887"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}